Lincoln Pharmaceuticals' Q2 FY 2025-26 Quarterly Results
- 16 Nov 2025
Result Summary
- Lincoln Pharmaceuticals Ltd reported a 0.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 0.3%.
- Its expenses for the quarter were up by 5.9% QoQ and 4.0% YoY.
- The net profit decreased 27.8% QoQ and decreased 24.1% YoY.
- The earnings per share (EPS) of Lincoln Pharmaceuticals Ltd stood at 9.98 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 170.60 | 169.34 | 171.19 | 0.7% | -0.3% |
Total Expenses | 141.79 | 133.95 | 136.40 | 5.9% | 4.0% |
Profit Before Tax | 28.81 | 35.39 | 34.78 | -18.6% | -17.2% |
Tax | 8.83 | 7.71 | 8.45 | 14.5% | 4.5% |
Profit After Tax | 19.98 | 27.68 | 26.33 | -27.8% | -24.1% |
Earnings Per Share | 9.98 | 13.82 | 13.15 | -27.8% | -24.1% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Lincoln Pharmaceuticals Ltd is a well-established company in the pharmaceutical industry. It primarily focuses on manufacturing and marketing pharmaceutical formulations. The company's product range includes a variety of therapeutic segments such as anti-infectives, cardiovascular, anti-diabetics, respiratory care, and women's health. Lincoln Pharmaceuticals is known for its commitment to innovation and quality, ensuring compliance with international standards. As of the latest available information up to October 2023, there are no major recent developments publicly available for Lincoln Pharmaceuticals Ltd. The company continues to operate in a highly competitive and regulated industry, which demands consistent innovation and adherence to stringent quality standards.
Revenue
In the second quarter of the fiscal year 2026 (Q2FY26), Lincoln Pharmaceuticals Ltd reported a total income of ₹170.60 crores. This represents a marginal quarter-over-quarter (QoQ) increase of 0.7% from ₹169.34 crores in Q1FY26. When compared to the same quarter in the previous fiscal year (Q2FY25), there is a slight year-over-year (YoY) decline of 0.3% from ₹171.19 crores. The stability in revenue indicates the company's ability to maintain its market presence amidst economic fluctuations. This nominal change in revenue could reflect stable demand for the company's products or effective pricing strategies.
Profitability
For Q2FY26, Lincoln Pharmaceuticals Ltd recorded a profit before tax of ₹28.81 crores, which marks a significant QoQ decrease of 18.6% from ₹35.39 crores in Q1FY26. On a YoY basis, there is a notable decline of 17.2% from ₹34.78 crores in Q2FY25. The tax expense for Q2FY26 amounted to ₹8.83 crores, showing an increase of 14.5% QoQ and 4.5% YoY. Consequently, the profit after tax for the quarter was ₹19.98 crores, reflecting a substantial QoQ decrease of 27.8% and a YoY decline of 24.1% from ₹27.68 crores and ₹26.33 crores, respectively. These figures suggest fluctuations in profitability metrics, influenced by changes in both revenue and tax expenses.
Operating Metrics
The earnings per share (EPS) for Q2FY26 was reported at ₹9.98, showing a decrease of 27.8% QoQ from ₹13.82 in Q1FY26 and a YoY decline of 24.1% from ₹13.15 in Q2FY25. This decrease in EPS mirrors the trends observed in profit after tax, indicating similar patterns in shareholder returns. Total expenses for Q2FY26 were ₹141.79 crores, representing a rise of 5.9% QoQ from ₹133.95 crores and an increase of 4.0% YoY from ₹136.40 crores. The increase in total expenses could be attributed to various factors including cost of goods sold, administrative expenses, or other operational expenditures. These operating metrics provide insight into the company's cost management and efficiency in the current quarter.